One-of-a-kind solution
for precision measurement of neurocognitive health

ViewMind is a digital health and artificial intelligence company that provides clinically validated solutions for precision assessment of neurocognitive disorders.


ViewMind’s technology is based on ocular digital phenotyping that measures the state of 16 cognitive domains and 19 brain related brain regions. It delivers groundbreaking levels of accuracy and correlates with biomarkers, neuroimaging and EEG.

Ongoing collaborations

About ViewMind

Based on 20 years of scientific research

ViewMind’s fundamental technology is based on research and development led by Dr. Gerardo Fernandez, ViewMind’s Chief Science Officer and Co-founder. ViewMind developed a technology that phenotypes eye movement responses to visual stimuli and the functioning of specific cognitive domains and related areas of the brain.

ViewMind collaborated with various academic institutions, hospitals, research facilities, key opinion leaders, and pharmaceutical companies to test and iterate on this breakthrough technology.

We are interested in additional partnerships for:

  • Commercial Phase I, II & III, IV pharmaceutical clinical studies for therapeutics that alter cognitive function.
  • Commercialization partners.
  • New studies with clinical centers, and patient advocacy groups.

Awards and Recognition

ViewMind has been recognized as an innovative healthcare
leader by these organizations:

ViewMind Leadership Team

We are a team of neuroscientists, serial entrepreneurs, seasoned
engineers, and data scientists.
  • Executives and founders

  • Board of Directors

  • Scientific Advisory Board 

Mark Edwards
CEO & Founder

Serial entrepreneur, CEO, chairman, founder, board member and builder of market leaders in both private and public companies.

Gerardo Fernandez PhD
CSO & Founder

Scientific researcher with 20+ years of experience researching eye movement patterns, neuroscience, and artificial intelligence.

Matias Shulz
COO & Founder

Seasoned entrepreneur, founder and digital health executive.

Denise Kelly
VP of sales and business development

Senior commercial executive from the medical devices industry.

Mario Parra, MD, PhD
Neuroscientific Officer

Specialist in the field of Alzheimer’s disease and related impairments.

Ariel Arelovich PhD

Full-stack software development leader and eye-tracking specialist.

Mark Edwards
Director & Chairman

Serial entrepreneur, CEO, chairman, founder, board member and builder of market leaders in both private and public companies.

Leesa Soulodre MBA

Founder and Managing Partner of R3i Ventures, a seed-stage VC Fund based in Luxembourg, Singapore and Silicon Valley.

Scarlett Chen

Managing Partner, Verge HealthTech Fund. Previously Managing Director at Prudential Corporation Asia & investment banker at Merrill Lynch & Barclays

Nicolás Tognalli PhD

Founder and Managing Partner of CITES, healthtech seed stage investment firm, and CVC arm of Grupo Sancor insurance group.

Francisco Lopera MD

Professor, Director and founder of the Antioquia Neuroscience Group at the University of Antioquia in Medellín, Colombia. Dr. Lopera is one of the world’s leading specialists on Alzheimer’s & neurodegenerative disorders.

Walter Greenleaf PhD

Dr. Greenleaf is a Stanford University research neuroscientist and medical product developer and one the world’s leading authorities in the use of virtual reality technology in healthcare.

Juan Granada MD

CEO of the cardiovascular research foundation CRF in New York. Dr. Granada is one of the leading researchers in the translational validation of novel cardiovascular therapies.

Mario Parra MD PhD

An award-winning neuroscientist for innovative research in Alzheimer’s biomarkers and a Professor at Strathclyde University.

To be updated on
ViewMind news please
click buttons

To contact ViewMind